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Abstract 
Purpose: This article aims to assess the Sudan National Health Insurance Fund (NHIF) medicines 
utilization trends and pattern between 2006 and 2010. 
Methods: A quantitative descriptive study was conducted to analyse the aggregate spending and 
utilization data. The aggregate medicine data used in the times series were collected from a large NHIF-
Sudan bulk purchasing system from 2006 to 2010.  The Anatomical Therapeutic Chemical 
(ATC)Classification System and Defined Daily Dose (DDD) methodologies were applied in the study for 
the period 2006 - 2010, 1st to 4th quarter of each year, ATC classes (14 in all),WHO ABC and VEN 
(vital, essential, non-essential) categories. Both descriptive and inferential statistics were used to 
analyse the data. 
Results: The total medicine utilization from 2006 to 2010 was 402.62 million DDD with an overall 
increase of 176.43 % over the period. The medicine classes that accounted for the highest utilization 
were medicines related to blood and blood-forming organs, followed by the cardiovascular system, 
general anti-infectives for systemic use, and those pertaining to the alimentary tract and metabolism. 
Among the most highly used medicines were folic acid, mefenamic acid and amlodipine tablets.  Further 
analysis indicate that there was a statistically significant difference between groups {F (4, 5270) = 
54.412, p < 0.001} and weak positive significant correlation between medicine utilization and both 
population coverage and number of patients (p < 0.001). 
Conclusion: The results show that medicine utilization in NHIF-Sudan significantly increased from 2006 
to 2010. Medicines for blood and blood-forming organs were the highest utilized class of medicines, 
while folic acid tablet was the most highly used medicine. 
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According to WHO, information and regular 
monitoring regarding appropriateness and 
efficiency of medicines use in developing 
countries are often lacking [1]. There has been a 
growing trend of medicine utilization  in the NHIF-
Sudan (National Health Insurance Fund-Sudan). 
In order to gain a better understanding of 
medicine services’ expenditure and trends, the 
policy makers in the NHIF-Sudan need to track 
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the access, utilization and use of medicines for 
evidence-based decisions.  
 
This research is the first of its kind to present 
medicine procurement in Sudan using a standard 
method ATC/DDD system, which is 
recommended by the WHO. This system allows 
national and international comparisons of 
medicine utilization studies [2].The findings are 
expected to enable the creation of accurate 
reports and studies to develop more successful 
medicine services, motivate pharmacy staff in the 
NHIF to improve and follow the established 
recommended and international standards, plan 
for better medicines consumption, improve the 
quality of statistics on medicines, facilitate 
national and international comparisons of 
medicine utilization and suggest a format for 
application to the entire medicine sector in 
Sudan.  
 
This article aims to assess the Sudan National 
Health Insurance Fund (NHIF) medicines 
utilization trends and pattern during the period 






This was a mixed observational retrospective 
and prospective study. A quantitative study was 
conducted to analyse the aggregate spending 
and utilization data. Aggregate medicine data 
managed by a large NHIF-Sudan bulk 
purchasing system from 2006 to 2010, were 




The research was approved (ref: 140211206) by 
the Directorate of Planning & Research of the 
NHIF-Sudan headquarters, NHIF-Sudan 
Committee of Research, the General Director of 
the NHIF-Sudan and the Minister of Welfare & 
Social Security. 
 
Study instrument and tools 
 
(a) ATC/DDD methodology 
 
Medicines utilization were expressed as DDDs 
and number of defined daily doses per 1000 
inhabitants per day (DDD/1000/day) or 
DDD/1000/ Inhabitant /Day(DID) as 
recommended by the WHO Working Group on 
Medicine Utilization. DDDs were calculated as 
per the guidelines for ATC classification and 
DDD assignment as provided by the WHO 
Collaborating Centre for Drug Statistics 
Methodology [3]. DDDs were calculated as in Eq 
1. 
 
Defined Daily Doses = (QS)/D ………….. (1) 
 
where Q is quantity of dosage units, S is strength 
of each dosage unit and D is DDD value 
assigned by WHO. 
 
DDD/1000/day (DID) for these medicines was 
calculated as in Eq 2.  
 
Number of DDDs per 1000 inhabitants per day = 
(QS /T D Ds)1000 …………………..…(2) 
 
where Q is quantity of dosage units,  S is 
strength of each dosage unit, T is Total sample 
size (i.e. population covered), D is DDD value 
assigned by WHO and Ds is duration of the study 
(i.e., usually 1 year, but can be shorter). 
 
The DDDs were compared in order to determine 
consumption patterns in 2006 and in 2010 and to 
assess overall consumption trends [4-7]. 
 
(b) Therapeutic category analysis 
 
Operational definition of variables 
 
The following are variables used in the study: 
 
(i) Dependent variables: Number of DDDs for 
individual medicines, DDD/1000 day for 
individual medicines;  
 
(ii) Independent variables: Years (2006-10); 1st to 
4th quarter of each year (1-4);   ATC classes (14 
classes): alimentary tract and metabolism, blood 
and blood-forming organs, cardiovascular 
system, dermatologicals, genito-urinary system 
and sex hormones, systemic hormonal 
preparations (excluding sex hormones and 
insulins), anti-infectives for systemic use, 
antineoplastic and immune-modulating agents, 
musculo-skeletal system, nervous system, 
antiparasitic products, insecticides and 
repellents, respiratory system, sensory organs; 
various ABC classes [4], and VEN categories [4]. 
 
Data management and statistical analysis 
 
Two independent pharmacists from NHIF-Sudan 
checked the aggregate spending data obtained 
from the NHIF database to ensure completeness 
and reliability of the data. Data were analysed 
with the computer program Excel and SPSS 
program (SPSS Inc, released 2009; PASW 
Statistics for Windows, version 18.0. Chicago: 
SPSS Inc.).   
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Descriptive statistics were used to present the 
dependent and independent variables. Normality 
of data was confirmed with a frequency chart 
(histogram), skewness and kurtosis. The mean 
and standard deviation were calculated for all 
normally distributed continuous variables. To 
describe nominal and ordinal variables, 
percentages, frequencies and contingency tables 
were used. The quarterly growth rate of NHIF-
Sudan medicine utilization (2006 to 2010) was 
presented in a line graph. Pearson correlation, 
ANOVA, i.e., one-way and two-way were used in 
the inferential statistical analyses. Tukey’s test 
was applied when the results of ANOVA were 
statistically significant. The level of statistical 




Medicine utilization trend in NHIF from 
2006 to 2010 
 
Figure 1 displays medicine utilization trends in 
NHIF-Sudan between 2006 and 2010. Total 
utilization via DDD methodology was 402.62 
million DDDs. The overall medicine utilization 
increased by 176.43% (from 11.46 million DDDs 
in Quarter 1, 2006 to 31.68 million DDDs in 
Quarter 1, 2010). The minimum medicine 
utilization per quarter was 9.29 million DDDs and 
the maximum recorded was 31.68 million DDDs. 
The mean utilization was 20.13 million DDDs 
(±6.39). 
 
Breakdown of medicine utilization by 
therapeutic class 
 
Analysis in this section was executed at the three 
levels of the ATC system, at first level 
(anatomical main group), at second level 
(therapeutic use), and at fifth level (subgroup for 
chemical substances).  
 
(a) Medicine utilization by main therapeutic 
class 
 
Table 1 shows the annual medicine utilization by 
main therapeutic class in NHIF-Sudan for the 
years from 2006 to 2010. The medicine classes 
that accounted for the highest utilization were 
medicines related to blood and blood-forming 
organs (27.84 %), followed by the cardiovascular 
system (20.78 %), general anti-infectives for 
systemic use (14.25 %) and the alimentary tract 
and metabolism (10.97 %). These classes were 
responsible for most of the medicine utilization 
(73.84%).  
 
Medicine utilization change and the percentage 
contribution of ATC main groups to total 
utilization from 2006-2010 are presented in Table 
3.  Among the top four groups, medicines related 
to blood and blood-forming organs made the 
largest contribution to the total increase in 
medicine utilization (130.66%), followed by the 
musculo-skeletal system (24.57 %), general anti-
infectives for systemic use (11.42 %) and the 
respiratory system (4.16 %). These four classes 
were responsible for most of the total increase in 
medicine utilization (170.81 %) (Table 3). 
 
In terms of average annual growth rate for the 
study period 2006- 2010, medicines for the 
musculo-skeletal system had the highest 
average (250.93 %), and those for the respiratory 





          Figure 1: Quarterly medicine utilization trends in NHIF-Sudan, 2006 to 2010 
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Table 1: Annual medicine utilization per ATC main group measured in DDD/1000 inhabitants/day, 2006 – 2010 
 
S/no. ATC/main group Utilization in DDD/1000 inhabitants/day 
2006 2007 2008 2009 2010 *2006-2010 
       
1 Blood and blood-forming organs 1.15 33.11 29.68 39.84 49.20 153.01 
2 Cardiovascular system 33.15 20.00 20.16 17.67 23.20 114.18 
3 General anti-infectives for systemic use 14.53 15.89 14.9 14.3 18.70 78.34 
4 Alimentary tract and metabolism 15.34 12.38 9.33 10.53 12.70 60.27 
5 Musculo-skeletal system 0.06 8.57 7.14 7.47 9.10 32.32 
6 Sensory organs 16.44 4.03 1.71 3.82 4.57 30.56 
7 Respiratory system 3.87 4.73 4.36 4.58 5.40 22.93 
8 Anti-parasitic products, insecticides and repellents 7.46 5.07 3.16 2.95 3.34 21.97 
9 Nervous system 2.73 3.41 2.34 3.04 3.60 15.13 
10 Genito-urinary system and sex hormones 1.75 2.24 2.8 2.27 2.46 11.51 
11 Systemic hormonal preparations, excluding sex 
hormones 
1.02 2.19 1.99 1.71 1.92 8.83 
12 Dermatologicals 0.01 0.07 0.07 0.04 0.05 0.23 
13 Antineoplastic and immuno-modulating agents 0.00 0.06 0.05 0.05 0.03 0.19 
Total   97.51 111.73 97.68 108.25 134.00 549.48 
*Medicines sorted in descending order, 2006-2010 
 



















Inhabitants/day   
change 







1 Alimentary tract and 
metabolism 
15.34 15.73 12.69 9.45 
-2.65 -7.20 
-4.63 
2 Blood and blood-forming 
organs 
1.15 1.18 49.22 36.65 
48.1 130.66 
155.78 
3 Cardiovascular system 33.15 34.00 23.2 17.27 -9.95 -27.05 -8.54 
4 Dermatologicals 0.01 0.01 0.05 0.04 0.04 0.11 49.53 
5 Genito-urinary system and sex 
hormones 
1.75 1.79 2.46 1.83 
0.71 1.93 
8.89 
6 Systemic hormonal 
preparations, excluding sex 
hormones 
1.02 1.05 1.92 1.43 
0.90 2.45 
17.13 
7 General anti-infectives for 
systemic use 
14.53 14.90 18.73 13.95 
4.2 11.42 
6.55 
8 Antineoplastic and immuno-
modulating agents 0.00 0.00 0.03 0.02 0.03 0.08 0.00 
9 Musculo-skeletal system 0.06 0.06 9.1 6.78 9.04 24.57 250.93 
10 Nervous system 2.73 2.80 3.6 2.68 0.87 2.36 7.16 
11 Anti-parasitic products, 
insecticides and repellents 
7.46 7.65 3.34 2.49 
-4.12 -11.20 
-18.2 
12 Respiratory system 3.87 3.97 5.40 4.02 1.53 4.16 -27.37 
13 Sensory organs 16.44 16.86 4.57 3.40 -11.9 -32.26 0.63 
Total  97.51 100.00 134.3 100.00 36.80 100.00 8.33 
*The percentage may not equal 100 due to rounding 
 
(a) Medicine utilization for second-level 
therapeutic subgroup 
 
Medicine utilization analysis was further broken 
down by second-level ATC classification. The 
second level of the ATC classification groups 
medicines of different pharmacological classes 
that have the same main therapeutic use. Table 
3 displays the top 12 therapeutic classes based 
on their level of utilization (DDD/1000/inhabitant 
/day). They represent approximately 19.05 % of 
the total number of therapeutic classes (at the 
second level), and accounted for 84.02 % of total 
medicine utilization for the period from 2006 to 
2010. The medicine classes that accounted for 
the highest utilization were antianaemic 
preparations (32.59 %), followed by 
antibacterials for systemic use  with 16.81 % and 
beta blocking agents (7.30 %). 
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Table 3: Medicine utilization of top 12 second-level therapeutic subgroups, based on retail prices (RP) 
SDG, 2006–2010 
 
S/no. ATC code Description 2006 2007 2008 2009 2010 *2006-2010 
1 B03 Antianaemic preparations 0.01 32.72 29.39 39.41 48.92 150.45 
2 J01 Antibacterials for systemic use 14.52 15.73 14.71 14.12 18.54 77.61 
3 C07 Beta blocking agents   7.67 6.89 6.9 6.05 6.23 33.73 
4 M01 
Anti-inflammatory and Antirheumatic 
products  
0.06 8.19 6.65 7.11 8.68 30.69 
5 S01 Ophthalmologicals 16.44 4.03 1.71 3.82 4.57 30.56 
6 C09 
Agents acting on the renin-angiotensin 
system 
16.05 3.65 3.17 3.53 4.17 30.56 
7 C08 Calcium channel blockers 1.63 5.54 5.99 4.56 8.31 26.04 
8 A02 Drugs for acid-related disorders 7.71 3.37 2.77 3.06 3.66 20.57 
9 A10 Drugs used in diabetes 6.66 3.51 2.89 3.37 4.07 20.49 
10 P01 Antiprotozoals 7.1 4.8 2.72 2.56 3.03 20.22 
11 R06 Antihistamines for systemic use 1.08 2.41 2.39 2.46 2.66 11.01 
12 A03 Drugs for functional gastrointestinal disorders 0.69 2.53 1.74 2.27 2.55 9.79 
Total     79.62 93.37 81.03 92.32 115.39 461.7 
*Medicines sorted in descending order, 2006-2010 
 
Table 4 shows the expenditure change between 
2006 and 2010 and the percentage contribution 
of second-level therapeutic subgroups to total 
medicine utilization.  
 
The top 12 therapeutic classes experienced an 
average annual utilization growth rate of 37.68 % 
between 2006 and 2010. Among the top three 
ATC level 2 therapeutic classes analysed were: 
antianaemic preparations made the largest 
contribution to utilization growth (132.94 %), 
followed by anti-inflammatory and antirheumatic 
products (23.43%), followed by calcium channel 
blockers (18.16%).In terms of average annual 
utilization growth rates, antianaemic had the 
highest average (736.32%) and antiprotozoals 
the lowest (- 19.17%) (Table 4). 
 
(b) Utilization analysis for the top leading 
therapeutic groups ATC second-level 
 
This section provides further analysis for the top 
three ATC level-2 therapeutic classes, which 
make a substantial contribution to total medicine 
utilization, as, identified in previous analysis.  For 
each class the top three medicines by fifth level 
were determined.  
 
(i) Antianaemic preparations 
 
Medicine utilization in this therapeutic class had  
a relatively high percentage share of total 
utilization for 2006 to 2010 (32.59 
 
%). Utilization in this therapeutic class increased 
from 0.01DID in 2006 to 48.92 DID in 2010, with 
an annual average growth rate of 736.32% 
(Figure 2). 
 
The top three medicine products within this 
therapeutic class were folic acid 5 mg tab 
(127.06 DID), ferrous sulphate + folic acid 
150+0.5mg cap (17.45 DID) and ferrous sulphate 
200 mg tab (2.80 DID) (Table 5). 
 
(ii) Anti-inflammatory and antirheumatic 
products 
 
Medicine utilization in this therapeutic class had 
a relatively high percentage share (in 2006 to 
2010, 16.81 % of total utilization). Utilization in 
this therapeutic class increased from 0.06 DID in 
2006 to 8.68 DID in 2010, with an annual 
average growth rate of 246.81% (Figure 3). 
 
The top three medicine products within this 
therapeutic class were mefenamic acid 500mg 
tab (11.10 DID), diclofenac Sodium 100 mg tab 
(8.72 DID) and diclofenac sodium 25mg tab (3.55 
DID) (Table 6). 
 
(iii) Calcium channel blockers 
 
Medicine utilization in this therapeutic class had  
Mousnad et al 



























Utilization   
change 
Total 
utilization   
change (%) 
1 B03 Antianaemic preparations 0.01 0.01 48.92 36.43 48.91 132.94 736.32 
2 J01 Antibacterials for systemic use 14.52 14.89 18.54 13.80 4.02 10.93 6.3 
3 M01 Anti-inflammatory and antirheumatic products  0.06 0.06 8.68 6.46 8.62 23.43 246.81 
4 C08 Calcium channel blockers 1.63 1.67 8.31 6.19 6.68 18.16 50.26 
5 C07 Beta blocking agents   7.67 7.87 6.23 4.64 -1.44 -3.91 -5.07 
6 S01 Ophthalmologicals 16.44 16.86 4.57 3.40 -11.87 -32.26 -27.39 
7 C09 Agents acting on the renin-angiotensin system  16.05 16.46 4.17 3.10 -11.88 -32.29 -28.61 
8 A10 Drugs used in diabetes 6.66 6.83 4.07 3.03 -2.59 -7.04 -11.58 
9 A02 Drugs for acid-related disorders 7.71 7.91 3.66 2.73 -4.05 -11.01 -16.99 
10 P01 Antiprotozoals 7.10 7.28 3.03 2.26 -4.07 -11.06 -19.17 
11 R06 Antihistamines for systemic use 1.08 1.11 2.66 1.98 1.58 4.29 25.28 
12 A03 Drugs for functional gastrointestinal disorders 0.69 0.71 2.55 1.90 1.86 5.06 38.65 
Subtotal-
utilization 
2 level top 
12  79.62 81.65 115.39 85.92 35.77 97.23 9.72 
Total 
medicines 
utilization   
97.51 100 134.30 100 36.79 100.00 8.33 
*Percentage may not equal 100 due to rounding up 
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          Figure 2: Antianaemic preparations: utilization trend in NHIF-Sudan, 2006 to 2010 
 
Table 5:  Antianaemic preparations utilization in NHIF-Sudan based on retail prices (RP) SDG, 2006-
2010 
 
S/N Drug name  (generic) 
Utilization in DDD/1000 inhabitants/day 
2006 2007 2008 2009 2010 *2006-2010 












2 Ferrous sulphate + Folic acid  150+0.5mg 
cap  
0.00 3.68 4.65 4.18 4.94 17.45 
3 Ferrous sulphate 200 mg  tab  0.00 1.00 0.82 0.23 0.74 2.80 
4 Vitamin  B12 (cyanocobalamine) 1mg/ml  
(Inj) 0.00 0.52 0.34 0.00 0.91 1.78 
5 Ferrous sulphate 50 mg syrup  0.00 0.15 0.19 0.13 0.19 0.66 
6 Vitamin B12 (cyanocobalamine) tab  0.00 0.06 0.09 0.15 0.12 0.41 
7 Erythropoitin inj 4000I.U   (Inj) 0.01 0.02 0.07 0.00 0.16 0.25 
8 Iron dextran  50 mg/ml  (Inj) 0.00 0.00 0.01 0.03 0.01 0.04 











*Medicines sorted in descending order, 2006-2010 
 
Mousnad et al 





































Figure 3: Anti-inflammatory and antirheumatic products trend in NHIF-Sudan, 2006 to 2010 
 
Table 6: Medicine utilization of anti-inflammatory and antirheumatic products based on retail prices 





Medicinename  (generic) 
Utilization in DDD/1000 inhabitants/day 
2006 2007 2008 2009 2010 *2006-2010 
1 Mefenamic acid 500mg tab  0.01 2.43 2.38 1.72 2.17 11.10 
2 Diclofenac  Sodium 100mg tab  0.01 1.06 0.71 0.86 0.92 8.72 
3 Diclofenac Sodium 25mg  tab 0.03 0.09 0.09 0.25 0.35 3.55 
4 Mefenamic acid 250mg tab  0.01 0.42 0.14 0.31 0.39 2.93 
5 Diclofenac Sodium 75 mg (Inj) 0.00 0.18 0.13 0.13 0.15 1.28 
6 Ibuprofen  400mg tab  0.00 0.37 0.08 0.25 0.35 1.05 
7 Diclofenac Sodium 50mg  tab   0.00 0.03 0.02 0.03 0.03 0.81 
8 Ibuprofen   200mg tab  0.00 0.00 0.01 0.00 0.01 0.59 
9 Indomethazine 25mg cap 0.00 0.17 0.12 0.12 0.12 0.53 
10 Ibuprofen  600 mg tab  0.00 0.70 0.59 0.68 0.96 0.12 
11 Indomethacine  100 mg susp 0.00 2.73 2.38 2.76 3.22 0.02 
12 Mefenamic acid 50mg/5ml susp 0.00 0.00 0.00 0.00 0.01 0.01 
Total   0.06 8.18 6.65 7.12 8.68 30.71 





































Figure 4: Calcium channel blockers utilization trend in NHIF-Sudan, 2006 to 2010 
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Drug name  (generic) 
 
Utilization DDD/1000/day 
2006 2007 2008 2009 2010 *2006-2010 
1 Amlodipine 5mg tab  1.33 2.27 2.29 0.81 3.77 10.47 
2 Amlodipine 10mg tab   0.08 0.57 1.30 2.27 3.34 7.56 
3  Nifedipine 20mg tab   0.00 1.80 1.87 1.08 0.83 5.57 
4  Nifedipine 10mg   tab  0.00 0.51 0.31 0.22 0.14 1.18 
5 Felodipine 5mg tab   0.22 0.36 0.20 0.17 0.22 1.16 
6 Diltiazem  HCL 60mg tab  0.01 0.03 0.02 0.02 0.01 0.09 
Total   1.64 5.54 5.99 4.57 8.31 26.03 
*Medicines sorted in descending order, 2006–2010 
 
a relatively high percentage share (for 2006-
2010, 5.64% of total utilization). Utilization in this 
therapeutic class increased from 1.63 DID in 
2006 to 8.31 DID in 2010, with an annual 
average growth rate of 50.26% (Figure 4). 
 
The top three medicine products within this 
therapeutic class were amlodipine 5 mg tab 
(10.47 DID), amlodipine 10 mg tab (7.56 DID) 
and nifedipine 20mg tab (5.57 DID) (refer to 
Table 7). 
 
Correlations between medicine utilization 
and population coverage per quarter 
2006-2010 
 
Pearson correlation analysis indicated that 
medicine utilization (DDDs) showed a very weak 
positive correlation with population coverage per 
quarter (r = 0.161, p < 0.001). 
 
Correlations between medicine utilization 
and number of patients per quarter 2006-
2010 
 
Pearson correlation analysis also showed a very 
weak positive correlation between medicine 
utilization (DDDs) with the number of patients 
(beneficiaries) (r = 0.090, p < 0.001). 
 
Differences in medicine utilization 
between years  
 
One-way ANOVA was used to examine the 
differences between medicine utilization among 
years.   There was a statistically significant 
difference between groups {F (4, 5270) = 54.412, 
p < 0.001}. Tukey post-hoc test revealed that the 
observed significant difference between the 
mean medicine utilization among the years lies 
between mean proportional medicine utilization 
for the years 2006(M=7.77, SD = 3.17) and 2010 
(M=9.43, SD = 0.03) (p < 0.001). Other 
differences were not significant. 
 
Differences in medicine utilization 
between quarters  
 
To examine the differences between medicine 
utilization between quarters, one-way   ANOVA 
was used.There was no statistically significant 
difference between groups {F (3, 5271) = 1.297, 
p = 0.273}.   
 
Differences in medicine utilization between ATC 
main groups in different quarters  
 
Factorial design two-way ANOVA was used to 
compare differences in mean medicine utilization 
between ATC main groups for different quarters. 
There was no significant differences between the 
ATC main groups in different quarters {F (36, 
5275) = 0.183, p = 1.000}. 
 
Differences in medicine utilization 
between ABC classes in different quarters 
2006-2010 
 
There was no significant differences showed by 
factorial design two-way ANOVA between the 
ATC main groups in different quarters (F (6, 
5275) = 1.786, p= 0.098). 
 
Differences in medicine utilization 
between VEN groups in different quarters 
2006-2010 
 
Factorial design two-way ANOVA showed no 
significant differences between the ATC main 
groups indifferent quarters {F (6, 5275) = 0.116, 




This study presented comprehensive descriptive 
and comparative medicine utilization data for a 
national health insurance scheme in Sudan 
between 2006 and 2010 using a standard 
recommended method (DDD methodology) 
which is a powerful tool for medicine utilization 
research. The results are useful for policy-
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makers in the planning and assessment of 
medicine policies to achieve health goals.  
 
The findings indicate a significant growth in 
medicine utilization in terms of DDDs, reflecting 
both demand and supply sides. This growth is 
most likely due to increases in medicine prices, 
high utilization rate by patients or expansion of 
insurance coverage. Since 2007, the NHIF 
formulary has been expanded to include generic 
and innovative medicines. Spending was driven 
by higher utilization of existing and newer 
medicines [8].Statistically, the trend of medicine 
utilization with regard to ATC classes, ABC 
classes and VEN show that the classes were no 
statistically significant differences across 
quarters. The findings indicate statistically 
significant difference in medicine utilization 
across years. The difference was however, 
statistically significant lower in 2006 and 2010. 
 
There were no significant differences in medicine 
utilization between years in general; medicine 
utilization was largely the same between the 
years because of the formulary list change in 
2007 and the intensive regulations enacted 
during this period [9]. A positive medicines list 
was available in NHIF-Sudan since 1996. Inter-
brand competition was introduced in NHIF-Sudan 
since 2002. This has successfully decreased the 
medicines prices to about two-fifth of the tender 
fund if the bases was the wholesale prices. In 
addition, it was found that medicine utilization 
has a significantly stronger correlation with 
number of population covered per year quarter 
than the number of patient visits per year quarter. 
This indicates that the high utilization rate 
depends on insurance coverage rather than 
frequency of patient visits. 
 
High medicine utilization was explained by four 
therapeutic classes, i.e., blood and blood-forming 
organs (B), the cardiovascular system (C), 
general anti-infectives for systemic use (J), and 
the alimentary tract and metabolism (A); all were 
responsible for most of the medicine utilization. 
Two of them (B and J) in addition to the musculo-
skeletal system (M) and respiratory system (R) 
were responsible for most of the contribution to 
total increases in medicine utilization between 
2006 and 2010. The other two classes (C) and 
(A) showed a significant fall between 2006 and 
2010. Musculo-skeletal system (M) showed 
significant increase in the same period and is 
one of the classes that made a high contribution 
to total utilization increase and was the fastest 
growing medicine class (an average of 250.93 
per cent per year). The fastest declining 
medicine class, in terms of medicine utilization, 
was systemic hormonal preparations, excluding 
sex hormones (H) (decreased by an average of -
8.57 % per year); probably in response to new 
restrictions imposed on the NHIF formulary in 
2007 [8]. 
 
In the second-level therapeutic subgroup, the 
classes that accounted for the highest utilization 
were antiemetic preparations (B03), followed by 
antibacterials for systemic use (J01) and beta 
blocking agents (C07).  Only one of them (B03) 
in addition to anti-inflammatory and anti-
rheumatic products (M01) and calcium channel 
blockers (C08) was responsible for the largest 
contribution to total utilization increases between 
2006 and 2010. The fastest growing drug class 
was anti-anaemic preparations and the fastest 
declining drug class, in terms of drug 
expenditure, was antiprotozoals. When analysing 
the correlation between these results and the 
morbidity and mortality trends in Sudan we found 
that the same pattern of diseases was reflected, 
as malnutrition, acute renal failure, malignant 
neoplasm, heart failure, pneumonia, and 
septicaemia; all are in the top 10 causes of 
mortality in hospitals [10]. 
 
International comparisons for medicine utilization 
are difficult, owing to differences in healthcare 
systems, culture and politics [11]. 
 
Most of the developing countries do not publish 
national statistics on drug use, and 
pharmaceutical companies maintain information 
private for trade reasons [12]. A survey used 
data from five African countries: Gambia, Ghana, 
Kenya, Nigeria and Uganda confirmed that 
antibiotics were widely available and 
inappropriately used in all settings [13]. 
Unfortunately, individual medications were not 
measured using same methods that were used in 
this study [2,3]. Only one study was found in the 
regions that could be used for comparing 
antibacterials for systemic use with the current 
results. Although NHIF-Sudan is not 
representative of the whole country, it can offer a 
general perspective as it covers about two-fifth of 
the Sudanese population; the results of the study 
show the general medicine trend in the country 
and could be used for future research. 
 
In Sudan, antianaemic drugs are usually 
prescribed for pregnant mothers although they 
are also used to treat anaemia resulting from 
treatment of cancer. In this study, folic acid tablet 
was the most common medicine used in this 
class. Nordic countries had a low utilization rate 
of antianaemic preparations [14]. In Australia, 
hydroxocobalamin was the medicine used the 
most in 2006 and 2007. There was slight 
increase (26%) in anti-anaemic preparation 
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utilization in 2006 (7.25 DID) and 2007 (9.18 
DID) [15] as compared with the present study 
(0.01 DID (in 2006) and 32.72 DID (in 2007)); 
327100%). In Malaysia, the anti-anaemic 
preparation utilization for 2006 (0.18 DID) and 
2007 (0.16 DID) was generally lower than the 
present study. The most commonly prescribed 
anti-anaemics in Malaysia in 2007 were 
erythropoietin injections (0.156 DDD/1000 
population/day) [16] and this was lower than in 
NHIF-Sudan.  
 
In Tanzania, antibacterial utilization in 2009 (4.99 
DID) was lower than in the present study [17]. In 
another finding, the antibacterial utilization in 
2006 and 2007 was almost 50 % less than in the 
present study [16]. Meanwhile, in Nordic 
countries, the average DID of utilization of 
antibacterials for systemic use was higher [14].In 
Australia, amoxicillin was the most widely used 
medicine in 2006 and 2007 (16.27 DID and 23.91 
DID, respectively). Antibacterial utilization in 
2006 and 2007 was higher than the present 
study, respectively [15].In Malaysia, the most 
commonly used antibacterials for systemic use 
was ampicillin whereas amoxicillin was the one 
most widely used in NHIF-Sudan and Tanzania. 
 
In Australia, atenolol was the most widely used 
beta blocker in 2006 and 2007, similarly to 
Malaysia and NHIF-Sudan. However, beta 
blocker utilization in 2006 and 2007 in Australia 
(26.58 DID and 26.83 DID), Nordic countries 
(46.26 DID and 46.30 DID) and Malaysia 
(25.71DID and 26.26 DID) was much higher than 
in the present study [14-16]. 
 
Previous findings indicated that a small number 
of items are responsible for largepercentage of 
the total NHIF budget [18], whereas around one-
fourth of number of items were responsible for 
only a small percentage of expenditure from the 
total budget [18].From the international 
comparison, it can be concluded that NHIF-
Sudan had higher utilization rate of antianaemic 
preparations compared with Malaysia, Australia 
and Nordic countries. Furthermore, NHIF-Sudan 
had a high utilization rate of antibacterials for 
systemic use compared with Malaysia and a low 
rate when compared to Australia and Nordic 
countries. Although there is high utilization rate of 
antibacterials for systemic use in developed 
countries, this can be explained by the large 
number of chemical entries in these countries 
compared to the developing countries where the 
utilization is restricted to narrow spectrum level of 
treatment [19]. In contrast, the present study also 
found more use of second and third line 
antibacterial treatment as compared to 
developed countries where they are more 
towards first-line of treatment. On the other hand, 
NHIF-Sudan had a lower utilization rate of beta 
blocking agents compared with Australia, Nordic 
countries and Malaysia. 
 
Limitations of the study 
 
There is a dearth of similar studies in the 
developing and low-and middle-income 
countries.  Thus, it was difficult to compare these 
present study findings with others.  In addition, 
the medicine use data for individual patient 
(prescriptions) was not available in NHIF 
databases. Only aggregate medicine data 
(spending, quantities and prices) was obtained 
from NHIF–Sudan headquarters. Therefore, 
medicine use variation by demographic 
characteristics (age-sex) was not captured in this 
study. A last point that is worth mentioning is the 
trend of drug utilization studied that was for the 
years 2006 ‐ 2010.  The findings are still 
important and useful. The list of medicines is still 
been used till today. No much changes in the 
policy and guidelines. These findings could be 





The findings of this study show that the total 
medicine utilization between 2006 and 2010 
significantly increased. The medicine classes 
that accounted for the highest utilization were 
medicines related to blood and blood-forming 
organs, followed by those related to the 
cardiovascular system, the general anti-infectives 
for systemic use and the alimentary tract and 
metabolism. This study provides evidence that all 
these quantification methods are very useful 
tools that pharmacy organizations can and 
should use to assess trends in drug 
consumption, manage the medicines list, identify 
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